YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an
update on the $3 million share
repurchase program (the "Share Repurchase Program") authorized by
the Company's Board of Directors on January
The Company reported that on September
30, 2022, the Company purchased 41,096 shares of common
stock at $ 7.1034 per share.
Anthony Hayes, CEO of Aikido
stated, "The Company's stock price is still below our book value,
so we are continuing to allocate capital under our repurchase
plan. The board believes in the Company and our plans moving
Additional shares may be repurchased from time to time in open
market transactions, or other means in accordance with Rule 10b5-1
of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and Rule 10b -18 of the
Exchange Act. The timing, number of shares repurchased, and prices
paid for the stock under this program will depend on general
business and market conditions as well as corporate and regulatory
limitations, including blackout period restrictions.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anticancer and antiviral therapeutics. The Company's platform
consists of patented technology from leading universities and
researchers, and we are currently in the process of developing an
innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including The
University of Texas at Austin and
University of Maryland at Baltimore .
Our diverse pipeline of therapeutics includes therapies for
pancreatic cancer, prostate cancer. We are constantly seeking to
grow our pipeline to treat unmet medical needs in oncology. The
Company is also developing a broad-spectrum antiviral platform that
may potentially inhibit replication of multiple viruses including
Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.